Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy
$267m Deal Expands Biotech’s Research
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
You may also be interested in...
Advances in small activating RNAs, pioneered by MiNA Therapeutics, have caught the eye of Eli Lilly, and could be the next platform to exploit gene control mechanisms to produce a new therapeutic modality.
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.